Showing results (1821-1830 of 1,873) with videos related to

Sort By:
Pageof 188
Journal of the American Heart Association|July 26, 2024
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCMCaroline J Coats, Ahmad Masri, Michael E Nassif, et al.
The New England Journal of Medicine|July 5, 2018
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Alejandra Gonzalez-Duarte, William D O'Riordan, et al.
Journal of the American College of Cardiology|January 6, 2026
Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic CardiomyopathyMichael E Nassif, Pablo Garcia-Pavia, Ahmad Masri, et al.
The New England Journal of Medicine|October 27, 2023
Patisiran Treatment in Patients with Transthyretin Cardiac AmyloidosisMathew S Maurer, Parag Kale, Marianna Fontana, et al.
Nature Medicine|September 24, 2021
Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trialCarolyn Y Ho, Sharlene M Day, Anna Axelsson, et al.
European Journal of Heart Failure|December 17, 2021
Diabetes and pre-diabetes in patients with heart failure and preserved ejection fractionAlice M Jackson, Rasmus Rørth, Jiankang Liu, et al.
The New England Journal of Medicine|July 5, 2018
Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D Benson, Márcia Waddington-Cruz, John L Berk, et al.
Kidney International|October 25, 2013
Whole-exome resequencing reveals recessive mutations in TRAP1 in individuals with CAKUT and VACTERL associationPawaree Saisawat, Stefan Kohl, Alina C Hilger, et al.
Pageof 188